Conolidine’s analgesic consequences stem from its conversation with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors in the central anxious technique, conolidine modulates alternate molecular targets. A Science Improvements study found that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://petert261fgh8.blogoxo.com/profile